Hi to all,
I hope everyone has great disease reversal, but the bottom line is, if going forward, you are never worse than your worst day in the past, Tovaxin is working.
From what I can tell, the people in the extension study wake up each morning looking for what function they have regained today. I hope it works that way for everyone, but that is not what the hope for Tovaxin is. Its purpose is to stop the attacks.
If when you wake up each day, you do not sense any regained function, you can be disappointed in your body's inability to restore itself. If on the other hand, you wake up and are feeling more disabled than you were at your worst point, then you can be disappointed in Tovaxin.
There may be a point during the 100 days that you sense things are starting to get better. Use the day before you get that feeling as your baseline. No matter what ups and downs you encounter going forward, if you don't drop below your baseline, Tovaxin is working.
You made mention in your 100 day club post that possibly 10 out of 150 folks would post.
My estimate that only 10 out of the 150 trial participants is based on the "good intentions, but no follow through" reality. Many people emailed that they were going to be keeping journals and posting regular results, but I have yet to see that happen.
When people feel bad, they look for answers. When people feel good, they hold their breath and hope it is for real. There is very little incentive to post that you are doing better. I hope people don't look at posting good news as being boastful. More likely than not, they are crossing their fingers and hope that the new found relief continues and don't want to jinx it.
Given the seemingly narrower path, i.e those who are not producing MRTC's or have been dropped for other reasons, the 150 number must be much smaller at this point. Thoughts?
It sounds like a very high percentage of trial participants will be continuing on into the extension study.
David McWilliams, chief executive officer of Opexa, commented, “The Phase IIb trial continues to be executed according to our plan and the level of dropouts has remained low. To date only 150 patient visits remain of the approximately 2,500 total visits comprising the trial. We look forward to reporting topline results on our primary endpoints in September. McWilliams continued, “We are also encouraged by the strong interest in the open label extension study for Tovaxin offered to all participants completing the Phase IIb study. Over 90% of patients who have completed the one-year TERMS study to date have elected to enroll in the extension study.”